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Abstract: Staphylococcus aureus is a commensal and pathogenic bacterium that causes infections
in humans and animals. It is a major cause of nosocomial infections worldwide. Due to
increasing prevalence of multidrug resistance, alternative methods to eradicate the pathogen
are necessary. In this respect, polyvalent staphylococcal myoviruses have been demonstrated
to be excellent candidates for phage therapy. Here we present the characterization of the
bacteriophage vB_SauM-fRuSau02 (fRuSau02) that was isolated from a commercial Staphylococcus
bacteriophage cocktail produced by Microgen (Moscow, Russia). The genomic analysis revealed
that fRuSau02 is very closely related to the phage MSA6, and possesses a large genome
(148,464 bp), with typical modular organization and a low G+C (30.22%) content. It can
therefore be classified as a new virus among the genus Twortlikevirus. The genome contains
236 predicted genes, 4 of which were interrupted by insertion sequences. Altogether, 78 different
structural and virion-associated proteins were identified from purified phage particles by liquid
chromatography-tandem mass spectrometry (LC-MS/MS). The host range of fRuSau02 was tested
with 135 strains, including 51 and 54 Staphylococcus aureus isolates from humans and pigs, respectively,
and 30 coagulase-negative Staphylococcus strains of human origin. All clinical S. aureus strains
were at least moderately sensitive to the phage, while only 39% of the pig strains were infected.
Also, some strains of Staphylococcus intermedius, Staphylococcus lugdunensis, Staphylococcus epidermidis,
Staphylococcus haemolyticus, Staphylococcus saprophyticus and Staphylococcus pseudointer were sensitive.
We conclude that fRuSau02, a phage therapy agent in Russia, can serve as an alternative to antibiotic
therapy against S. aureus.
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1. Introduction
Staphylococcus aureus is a commensal and pathogenic bacterium that causes opportunistic
infections in humans and animals. Approximately 20% of humans have persistent and 30% sporadic
nasal S. aureus colonization [1]. As a pathogen, S. aureus causes a broad spectrum of infections in
humans ranging from simple abscesses to fatal sepsis, including pneumonia, endocarditis, meningitis,
mastitis, food poisoning, and toxic shock syndrome [2]. Currently the antibiotic resistance of this
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species poses a threat to public health. Even though the incidence of severe infections caused by
methicillin-resistant S. aureus (MRSA) is decreasing [3], MRSA still is an important cause of nosocomial
infections worldwide [4,5]. The emergence of multidrug resistance results in difficulties in eradication
of the pathogen with the use of conventional therapies and thus requires development of alternatives
to antibiotic-based therapies.
One promising alternative to treat infections caused by antibiotic resistant bacteria is phage
therapy, where the natural predators of bacteria (bacteriophages, phages) are used to kill the
pathogens [6–8]. The history of phage therapy has been extensively reviewed elsewhere [9,10] and
is not discussed here. To be considered safe, phage therapy has to meet a number of criteria: phages
used for therapeutic purposes need to be strictly lytic and they should not carry known genes coding
for toxins or other harmful substances [11]. Furthermore, the host bacteria used for phage production
should have as few prophages as possible and the therapeutic phage preparation should not contain
high concentration of bacterial toxins.
All known S. aureus phages belong to order Caudovirales, i.e., they are tailed phages with an
icosahedral capsid that surrounds the double-stranded DNA genome [12,13]. Staphylococcal phages
can be classified into three categories: (1) podoviruses with <20 kb genomes; (2) siphoviruses with
~40 kb genomes; and (3) myoviruses with >125 kb genomes [12]. Of these phage groups, staphylococcal
siphoviruses are generally temperate and often carry genes promoting bacterial virulence [13], which
makes them inappropriate for therapeutic applications. Staphylococcal podoviruses, on the other
hand, are strictly lytic but extremely rare and difficult to find [14]. From therapeutic point of view,
myoviruses are considered the most interesting staphylococcal phages [14,15].
Many of the staphylococcal myoviruses are classified into the genus Twortlikevirus of the
Spounavirinae subfamily and are related at genetic and proteomic level [16]. The Twortlikevirus genus
consists of phages with genomes of 127–141 kb, low G+C content (30–31%), and 183 to 217 open
reading frames (ORFs) [17]. Currently, this genus contains over 25 members, including phage Twort,
G1 [18], K [19], MSA6 [20], GH15 [21], Romulus, and Remus [17]. A typical feature for Twort-like
viruses is the presence of long terminal repeats (LTRs), several thousand base pair-long direct repeats
at the ends of the genome. The nucleotide sequence and length of LTR regions differ among the
representatives of the genus and may influence the host range [15]. Twort-like viruses are also known
for their broad host range. This phenomenon is mainly accounted to the presence of multiple receptor
binding proteins in the viral capsid that allow them to utilize at least two adsorption apparatuses
and recognize different structures [22]. This feature, together with their strictly lytic life cycle, makes
Twort-like viruses particularly suitable for clinical applications [15].
In this paper, we report the isolation and analysis of a Twort-like S. aureus phage,
vB_SauM-fRuSau02 (fRuSau02). The phage was isolated from a therapeutic bacteriophage product
from Microgen Company (Moscow, Russia). The product was purchased in a pharmacy in Saint
Petersburg, Russia, and was meant to treat infections typically caused by S. aureus. However,
no information about the phage composition or the efficacy of the phage cocktail was available.
Phage fRuSau02 was the only phage we were able to isolate from this product. Here, we show the
analysis of fRuSau02 at a genetic and proteome level, the latter of which allowed us to identify the
majority of the phage structural proteins. Additionally, we provide an insight into the reasons why this
phage might be well-suited for clinical applications by testing its growth efficiency and host range with
a broad range of human and porcine isolates. We also present an evaluation of the fRuSau02 production
in different host strains, with intention to select an optimal producer strain for clinical applications.
2. Materials and Methods
2.1. Bacterial Strains, Phages and Media
The bacterial strains used in this work are described in Table S1. The collection of human isolates
used in this study was provided by The Hospital District of Helsinki and Uusimaa Laboratories
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(HUSLAB), Finland. All staphylococcal and phage incubations were done at 37 ◦C using Luria Broth
(LB) [23] medium. Soft agar medium included additionally 0.35 or 0.4% (w/v) agar (Becton Dickinson,
Franklin Lakes, NJ, USA), and LB agar plates were solidified with 1.5% (w/v) of agar. fRuSau02 was
isolated using a clinical S. aureus strain 13KP (Table S1) as a host, and the same strain was then used as
a standard host strain for the phage. The phage lysates were produced from semiconfluent soft-agar
plates as described elsewhere [23].
2.2. Phage Purification
The fRuSau02 lysate (5 × 1010 plaque-forming units (PFU)/mL) was ultrafiltrated with Amicon
Ultra-4 (100 kDa) Centrifugal Filter Units (Merck Millipore, Billerica, MA, USA) to one quarter of the
initial volume. Three volumes of chromatography buffer A (20 mM Tris-Cl, pH 7.5) were added and
the ultrafiltration was repeated. The volume was adjusted with buffer A. The ultrafiltrated phage
sample was then purified with ion exchange chromatography (IEX) using Äkta Purifier (GE Healthcare,
Chicago, IL, USA) and a CIM QA-1 tube monolithic column with a 6-µm pore size (BIA Separations,
Ajdovščina, Slovenia). The sample was injected to the column in buffer A, washed with buffer A
containing 350 mM NaCl and eluted with buffer A with 450 mM NaCl. The phage-containing fractions
of two purification batches were pooled, and an Amicon Ultra was used to concentrate the product
and to change the buffer to TM (50 mM Tris, pH 7.5–10 mM Mg2SO4). Purified phage samples were
stored at 4 ◦C.
2.3. Electron Microscopy
IEX-purified phage lysate was pelleted by centrifugation at 16,000× g, 4 ◦C, for 2 h and
resuspended into 0.1 M ammonium acetate. Subsequently, the phage particles were allowed to
sediment on 200 mesh pioloform-coated copper grids for 1 min and stained negatively using 3% uranyl
acetate. Samples were examined with a JEOL JEM-1400 transmission electron microscope JEOL Ltd.,
Tokyo, Japan) under 80 kV at the Electron Microscopy Unit (Institute of Biotechnology, University
of Helsinki, Helsinki, Finland). Pictures were taken using Gatan Orius SC 1000B bottom-mounted
Charged Coupled Device (CCD)-camera (Gatan Inc., Pleasanton, CA, USA). Ten virions were measured
and data were used to calculate mean values and standard deviations.
2.4. Infection Growth Curves
Overnight bacterial cultures of S. aureus 13KP were diluted to a ratio of 1:100 in fresh LB medium,
and 180-µL aliquots were distributed into honeycomb plate wells (Growth Curves Ab Ltd., Helsinki,
Finland), where they were mixed with 20-µL aliquots of different fRuSau02 phage stock dilutions.
The phage stock and bacterial culture were mixed to achieve multiplicity of infection (MOI) values
ranging between 5 × 10−7 and 500. A negative control was obtained by mixing 20 µL of phage stock
with 180 µL of LB, whereas the positive control consisted of 180 µL of bacterial culture and 20 µL of
fresh LB medium. The growth experiment was carried out at 37 ◦C using a Bioscreen C incubator
(Growth Curves Ab Ltd.) with continuous shaking. The optical density at 600 nm (OD600) of the
cultures was measured every 1 h. The averages were calculated from values obtained for the bacteria
grown in five parallel wells.
2.5. DNA Isolation and Phage Genome Sequencing
fRuSau02 DNA was isolated from crude phage lysate with Invisorb Spin Virus DNA Mini
Kit (Stratec Biomedical, Birkenfeld, Germany). Sequencing was performed at the Institute for
Molecular Medicine Finland (FIMM) Technology Centre Sequencing Unit [24]. For next-generation
sequencing, the DNA library was constructed with Nextera sample prep kit (Illumina, San Diego,
CA, USA). Paired-end sequencing was done using Illumina MiSeq PE300 sequencer (Illumina,
San Diego, CA, USA) with the read length of 300 nucleotides. TheA5 (Andrew And Aaron’s
Awesome Assembly)-miseq integrated pipeline for de novo assembly of microbial genomes was used
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to obtain the genome sequence [25]. fRuSau02 sequence was submitted to GenBank with accession
number MF398190.
2.6. Determination of Physical Ends of the Phage Genome
To determine the physical ends of the phage genome, the approximate positions of the terminal
repeats were estimated based on the sequence read numbers using the Integrative Genomics Viewer
(IGV) [26,27]. The genome was manually edited according to the estimated physical ends and
subjected to virtual digestions with several restriction endonucleases. Two enzymes (NheI and
PstI), yielding identifiable end fragments, were used to digest the fRuSau02 DNA, and the resulting
fragment distributions were compared to the virtual digestions. The NheI fragments corresponding
to the physical ends of the phage genome were isolated from a preparative agarose gel and ligated
to pUC19 digested with XbaI and SmaI. The ligation mixtures were used as a template for PCR
reaction with pUC19—specific primers Puc19-F (CCTCTTCGCTATTACGCCAG) and pUC19-R
(CAACGCAATTAATGTGAGTTAGCT). The PCR products corresponding to the sizes of the genome
end fragments (2.7 kb and 4.5 kb for left and right ends, respectively) were isolated from a preparative
agarose gel and sequenced with ABI3730XL DNA Analyzer (Applied Biosystems, Foster City, CA,
USA) capillary sequencer with primers Puc19-F and Puc19-R at FIMM [24]. The sequence information
was used to deduce the actual sequence of the genome ends and terminal repeats.
2.7. In Silico Analysis of Phage Genome
The phage genome was autoannotated using Rapid Annotation Using Subsystem Technology
(RAST [28] and proofread manually. Promoters and terminators were predicted using PePPER [29] and
ARNold [30,31], respectively, with subsequent manual verification. The promoter consensus sequence
was analyzed using MEME [32]. A comparative genome figure was generated using CGView [33].
The genome-wide comparison of bacteriophages was conducted with EMBOSS Stretcher [34].
Phylogeny analysis was conducted with the VICTOR Virus Classification and Tree Building
Online Resource [35] using the Genome-BLAST Distance Phylogeny (GBDP) method [36] under
settings recommended for prokaryotic viruses [35]. The resulting intergenomic distances (including
100 replicates each) were used to infer a balanced minimum evolution tree with branch support via
FASTME including Subtree Pruning and Regrafting (SPR) postprocessing [37] for the formula D0.
The tree was rooted at the midpoint [38] and visualized with FigTree [39]. Taxon boundaries at the
species, genus and family level were estimated with the OPTSIL program [40], the recommended
clustering thresholds [35] and an F value (fraction of links required for cluster fusion) of 0.5 [41].
2.8. Proteome Analysis
IEX-purified phages were concentrated by centrifugation for 2 h at 4 ◦C and 16,000× g. Prior to
digestion of proteins to peptides with trypsin, the proteins in the samples were reduced with
tris(2-carboxyethyl)phosphine (TCEP) and alkylated with iodoacetamide. Tryptic peptide digests were
purified by C18 reversed-phase chromatography columns [42] and the mass spectrometry (MS) analysis
was performed on an Orbitrap Elite Electron-Transfer Dissociation (ETD) mass spectrometer (Thermo
Scientific, Waltham, MA, USA), using Xcalibur version 2.7.1, coupled to an Thermo Scientific nLCII
nanoflow High Pressure Liquid Chromatography (HPLC) system. Peak extraction and subsequent
protein identification was achieved using Proteome Discoverer 1.4 software (Thermo Scientific).
Calibrated peak files were searched against the fRuSau02 and Staphylococcus aureus subsp. aureus ST398
proteins (ASM188707v1, NCBI) by a SEQUEST search engine. Error tolerances on the precursor and
fragment ions were ±15 ppm and ±0.6 Da, respectively. For peptide identification, a stringent cut-off
(0.5% false discovery rate) was used. The LC-MS/MS was performed at the Proteomics Unit, Institute
of Biotechnology, University of Helsinki.
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2.9. Host Range Screening
The fRuSau02 host range was analyzed by spot assay for most of the bacterial stains studied.
Some pig isolates failed to grow on soft agar, and their sensitivity was studied by a liquid culture
method. For this, bacteria were cultured overnight in Brain Heart Infusion (BHI) medium (Becton,
Dickinson and Company, Franklin Lakes, NJ, USA). Cultures were diluted 1:100 in BHI and aliquoted
into 200 µL aliquots to 96-well plates. To these, 10 µL of phage fRuSau02 (6.8 × 106 PFU) was added
and the plate was incubated at 37 ◦C with moderate shaking. For non-infected controls, 10 µL of
LB was added instead of the phage. Each strain was studied in triplicate wells. Bacterial growth
was monitored by measuring OD600 with FLUOstar OPTIMA plate reader (BMG LABTECH GmbH,
Ortenberg, Germany) at 60 min intervals for 4 h, and the inhibition of growth in phage-infected wells
compared to non-infected control wells indicated a sensitive strain.
2.10. Efficiency of Plating and Adsorption Assay
Bacterial strains were checked by the efficiency of plating (EOP), as described earlier [43]. In brief,
S. aureus strains 13KP, Newman, TB4, and tagO were pre-grown for 2–3 h at 37 ◦C. Subsequently
300 PFU of phage was mixed with 90 µL/OD600 of bacterial culture and 3 mL of soft agar (0.35% LB
agar) and poured over an LB plate. Following 24 h incubation at 37 ◦C, PFUs were counted and the
size and morphology of the plaques was evaluated. The experiment was performed in triplicates, and
negative controls without the bacteriophages were prepared. To estimate the adsorption of phage
particles on the surface of different S. aureus strains, a phage adsorption assay was conducted as
described earlier [44]. Briefly, approximately 2.5 × 106 PFU of fRuSau02 was mixed with 500 µL
of bacterial overnight cultures (OD600 = 3.3). The suspension was incubated at room temperature
for 5 min, centrifuged at 16,000× g for 3 min, and the phage titer remaining in the supernatant
was determined. The phage titer in the control supernatant was set to 100%. LB was used as a
non-adsorbing control. Each assay was performed in triplicates.
2.11. Staphylococcal Enterotoxin Measurement
Staphylococcal enterotoxins were measured from the phage lysates with the Transia Plate
Staphylococcal Enterotoxins assay (BioControl Systems, Inc., Bellevue, WA, USA) using staphylococcal
enterotoxin A (Sigma-Aldrich, St. Louis, MO, USA) as standard. Absorbance at 450 nm was recorded
with Hidex Sense Microplate Reader (Hidex, Turku, Finland).
3. Results
3.1. Isolation and Morphology
Phage fRuSau02 was isolated from the Staphylococcus bacteriophage cocktail produced by the
Microgen Company (Moscow, Russia; series: H52, 0813, PN001973/01). Electron microscopy of
the negatively-stained fRuSau02 particles revealed that the phage had an icosahedral head with a
contractile tail and a basal tuft attached to the tail (Figure 1). The dimensions of the head were 86 nm
(vertical) and 83 nm (horizontal), and the tail length without the base plate was 192 nm. Standard
deviations were 3.1, 2.8, and 5.3 nm respectively. Only one particle with contracted tail was found
(Figure 1b), and the contracted part was 96 nm. Based on the morphological characteristics, phage
fRuSau02 belongs to the order Caudovirales and the family Myoviridae [45,46].
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Figure 1. Electron micrographs of negatively stained vB_SauM-fRuSau02 (fRuSau02) particles. Phage 
particles with non-contracted (a) and contracted (b) tails are shown. Bars represent 100 nm. 
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culture. The study showed that fRuSau02 is able to efficiently lyse the culture at MOIs above 5 × 10−5 
(Figure 2), whereas at MOIs values below this limit there was no lysis observed (data not shown). 
Additionally, there was no re-growth of the bacterial culture observed within the 24 h time period of 
the experiment. In coherence, the prolonged incubation of the infected bacteria in the soft agar did 
not result in emergence of resistance within the first 7 days of incubation indicating low rate of phage-
resistance development among the bacteria. Efficient infection and complete lysis of bacterial culture 
with very low MOI values may be a common feature of twort-like phages, as MOI 1 × 10−4 was earlier 
shown to be optimal for the production of high-titer lysate of phage MSA6 [20]. 
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Figure 1. Electron micrographs of negatively stained vB_SauM-fRuSau02 (fRuSau02) particles.
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3.2. The Efficiency of Infection
To examine the efficiency of fRuS u02 infection, S. aureus 13KP was infected in liquid culture at
differen MOI val es and the b cterial growth was assessed by following the optical d nsity of the
culture. The study showed that fRuSau02 is able to efficiently lyse the culture at MOIs above 5 × 10−5
(Figure 2), whereas at MOIs values below this limit there was no lysis observed (data not shown).
Additionally, there was no re-growth of the bacterial culture observed within the 24 h time period
of the experiment. In coherence, the prolonged incubation of the infected bacteria in the soft agar
did not result in emergence of resistance within the first 7 days of incubation indicating low rate of
phage-resistance development among the bacteria. Efficient infection and complete lysis of bacterial
culture with very low MOI values may be a common feature of twort-like phages, as MOI 1 × 10−4
was earlier shown to be optimal for the production of high-titer lysate of phage MSA6 [20].
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Figure 2. Growth curves of Staphyloc cus aureus infected with fRuSau02. Bacteria were
cultured with d fferent con e trations of phage s in Luria Broth (LB) at 37 ◦C. Each curve
represents the average results for five replicates, error bars represent standard deviation (SD).
MOI: multiplicity of infection.
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3.3. General Genome Analysis
The linear double-stranded DNA of fRuSau02 comprises 148,464 bp encoding 236 putative ORFs
(Figure 3, Table 1). The two terminally redundant 8076 bp long ends encode 20 putative terminal
repeat proteins. Sixty-five of the predicted genes are transcribed from the minus strand, including the
genes likely to be involved in bacterial cell lysis (holin and numerous putative membrane proteins).
Additionally, two single genes from the terminally redundant region, treI and treM, are also encoded on
the minus strand. In silico analysis predicted the presence of 43 bacterial promoters and 32 terminators.
The analysis failed to identify promoters within the 39,000–66,500 bp range in the fRuSau02 genome
where the structural proteins are encoded. The consensus sequence of the promoters was identified
(Figure 4 and Table S2). Interestingly, three predicted promoters located in front of spliced or intron
encoded genes (lysK.1, ksaI, I-MsaI) presented a distinctive promoter sequence that did not follow
the consensus sequence (Table S2). In addition to protein-coding sequences, three functional transfer
RNA(tRNA) genes encoding tRNAMet, tRNAPhe, and tRNAAsp were detected. Additionally, no known
genes encoding integrases, lysogeny- or virulence-associated or toxic proteins were identified and
therefore this bacteriophage can be considered as virulent and potentially safe for phage therapy.
Similarly to phage K, the genome of fRuSau02 completely lacks GATC sites that could be recognized
by host-encoded restriction endonucleases [19].
Table 1. The structural proteins of phage fRuSau02 identified using liquid chromatography tandem
mass spectrometry (LC-MS/MS).
Locus Name No of AA MW * [kDa] pI * (calc.)
RS_018 TreR, terminal repeat encoded protein R 156 17.8 3.78
RS_033 phage structural protein 105 11.8 6.76
RS_036 phage structural protein 64 7.6 4.65
RS_037 phage structural protein 245 28.6 6.58
RS_041 phage structural protein 57 6.8 5.26
RS_042 phage structural protein 160 18.8 4.64
RS_046 putative membrane protein MbpR 91 10.9 5.01
RS_048 phage structural protein 372 42.2 4.84
RS_050 phage structural protein 138 16.0 5.22
RS_051 HmzG, DNA-binding protein 100 11.3 4.91
RS_055 phage structural protein 87 10.1 5.91
RS_059 Lig, putative DNA or RNA ligase 298 35.0 5.57
RS_061 Phr, putative PhoH-related protein 246 28.6 5.29
RS_063 Rbn, phage ribonuclease H 141 15.8 7.27
RS_067 phage structural protein 75 9.2 9.95
RS_070 putative membrane protein MbpS 263 29.3 8.82
RS_072 LysK.1, phage lysin 209 23.1 9.66
RS_074 LysK.2, phage lysin 267 29.8 9.45
RS_075 HolA, phage holin 167 18.1 4.25
RS_078 DmcB 69 8.0 5.97
RS_080 putative membrane protein MbpC 108 13.0 5.54
RS_082 putative membrane protein MbpD 88 10.3 8.31
RS_085 Ter.1, phage terminase 65 7.7 9.60
RS_087 Ter.2, phage terminase 515 59.7 6.10
RS_088 phage structural protein 266 29.8 5.30
RS_094 Prt, portal protein 563 64.0 6.42
RS_095 Pro, prohead protease 257 28.6 5.01
RS_096 phage structural protein 318 35.9 4.46
RS_097 Mcp, major capsid protein 463 51.2 5.24
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Table 1. Cont.
Locus Name No of AA MW * [kDa] pI * (calc.)
RS_098 phage structural protein 98 11.3 9.42
RS_099 phage structural protein 302 34.1 5.24
RS_100 phage structural protein 292 33.7 5.82
RS_101 phage structural protein 206 23.7 10.32
RS_102 phage structural protein 278 31.7 4.79
RS_104 Tsp, major tail sheath protein 587 64.5 4.98
RS_105 TmpA, tail tube protein 142 15.9 5.54
RS_109 phage structural protein 103 12.2 6.13
RS_110 phage structural protein 152 18.1 4.79
RS_111 TmpB, tail morphogenic protein 178 20.9 4.40
RS_112 TmpC, phage DNA transfer protein 1351 143.7 9.11
RS_113 TmpD, tail murein hydrolase 808 91.2 6.74
RS_114 TmpE, putative peptidoglycan hydrolase 295 34.6 4.60
RS_115 Glycerophosphoryl diester phosphodiesterase 848 96.0 4.96
RS_116 phage structural protein 263 29.3 8.19
RS_117 phage structural protein 174 19.9 4.61
RS_118 BmpA, baseplate morphogenetic protein 234 26.6 4.77
RS_119 BmpB, baseplate morphogenetic protein 348 39.2 4.86
RS_120 TmpF, tail morphogenetic protein 1019 116.2 5.08
RS_121 BmpC, baseplate morphogenetic protein 173 19.2 5.39
RS_122 TmpG, tail morphogenetic protein 1152 129.0 5.19
RS_124 receptor binding protein 640 72.6 7.39
RS_126 receptor binding protein 458 50.3 6.27
RS_127 DhlA, DNA helicase 582 67.2 5.85
RS_129 DhlB, DNA helicase 480 54.5 5.72
RS_132 RncB, recombination nuclease B 639 73.4 5.19
RS_133 Asf, anti-sigma factor 198 23.2 6.81
RS_137 phage structural protein 202 23.6 5.72
RS_139 NrdE, ribonucleotide reductase 704 80.1 5.64
RS_140 NrdF, ribonucleotide reductase 349 40.4 4.78
RS_141 phage structural protein 109 12.4 4.68
RS_143 phage structural protein 179 21.1 6.95
RS_152 phage structural protein 423 46.8 4.75
RS_153 Rec.1, phage recombinase 74 7.9 6.61
RS_155 Rec.2, phage recombinase 315 35.7 5.16
RS_157 Sig, sigma factor 220 26.6 5.36
RS_158 phage structural protein 210 23.2 4.84
RS_159 TmpH, phage major tail protein 73 7.9 4.54
RS_160 phage structural protein 86 10.3 5.91
RS_163 putative membrane protein MbpG 122 14.0 5.95
RS_165 phage structural protein 178 20.8 7.47
RS_168 phage structural protein 287 32.3 5.76
RS_169 phage structural protein 243 28.3 5.34
RS_170 phage structural protein 152 17.8 4.98
RS_173 putative membrane protein MbpH 132 15.4 8.94
RS_175 phage structural protein 80 9.4 9.31
RS_181 phage structural protein 98 11.3 7.24
RS_196 phage structural protein 87 9.9 10.05
RS_206 NadV, nicotinamide phosphoribosyltransferase 489 56.1 5.44
* MW: Molecular weight, pI: Isoelectric point.
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GC content of the fRuSau02 genome (black). Selected gene functions are indicated. The figure was
generated with CGView [33].
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3.4. Comparative Genome Analysis
Bioinformatic analysis of the fRuSau02 genome revealed that the phage has a genome size and
organization typical for Twort-like viruses [15]. It is most closely related to phage MSA6 (JX080304),
the two viruses showing 99.6% identity at the nucleotide level. The DNA sequence comparison
with other Twort-like viruses revealed identity in the range of 39.0–96.0% (Table S3). The highest
identity was observed with phages A5W (EU418428)—96.0%, Staph1N (JX080300)—96.0%, and Fi200W
(JX080303)—95.1%. The genomic comparison of fRuSau02 with phages K and Twort showed identity
rates of 93.5% and 46.5%, respectively. Figure 3 shows a BLASTN comparison of the genomes of
phages fRuSau02, K and Twort. The whole-genome level nucleotide phylogeny analysis of fRuSau02
and the 34 phage genomes described in Table S3 showed that fRuSau02 clusters in the same species
with A5W, Staph1N, MSA6, Fi200W, and 676Z (Figure 5). The analysis yielded average support of 16%
and the OPTSIL clustering resulted altogether to 22, 2, and 1 clusters at species, genus, and family
levels, respectively.Viruses 2017, 9, 258  11 of 19 
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Most fRuSau02 nucleotide differences to MSA6 were single base pair substitutions or small indels
in intergenic regions. There were 25 coding regions having differences to MSA6, eight of which had
silent mutations, leading to proteins with 100% amino acid identity with their MSA6 counterparts
(terminal repeat encoded protein TreP, phage terminase Ter.2, tail morphogenetic proteins TmpB a d
TmpG, DNA helicase DhlA, DNA primase/DNA helicase Pri, rib nucleotide reductase NrdE, and
intron encoded endonuclease I-MsaI). Ten proteins had difference(s) to the corresponding proteins i
MSA6 but showed 100% amino acid identities to their homologs in other Twort-like viruses: terminal
repeat encoded pr tein TreK was identical to phage G1 ORF159 but showed only 87.4% identity
to MSA6 TreK. Terminal repeat encoded protei TreG was identical to phage K Gp007, putative
membrane protein MbpP to G1 ORF007, hypothetical protein DmcA to G 122 of phage JD007, putative
membrane pr tein MbpE to phage G1 ORF120, major tail sheath Tsp to phage K Gp166, hyp thetical
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protein RS_209 to Team1 Gp041, putative receptor binding protein RS_126 to SA5 ORF40, terminal
repeat encoded protein TreB to A5W TreB and to G1 ORF231, and putative portal protein Prt to G1
ORF014. Each of these proteins had one to two amino acid difference(s) to their MSA6 homologs.
Seven proteins had at least one amino acid (according to present knowledge) unique to fRuSau02, i.e.,
have not been observed in homologous proteins of any other Twort-like virus: putative membrane
protein MbpC, tail morphogenetic protein TmpC, putative receptor binding protein RS_124, putative
polymerase-associated exonuclease PolA.2, putative RNA polymerase sigma factor Sig, hypothetical
protein RS_200, and putative membrane protein MbpI.
Of the “unique” fRuSau02 proteins, RS_124 is of outmost interest. It is 98.1% identical at the
amino acid level to the orf103 gene product of phage ΦSA012, shown to be one out of two receptor
binding proteins (RBPs) of this phage [22]. Phage fRuSau02 RS_124 has histidine in position 306, where
all the other Twort-like viruses sequenced so far have proline. The residue 306 is part of a carbohydrate
binding domain, which is formed by amino acids 213–336. Preliminary structural modelling of this
region showed that H306 fits nicely into an anti-parallel β-sheet structure, which is completely distorted
by H306P change (not shown). This suggests that the structure of the receptor binding protein of
fRuSau02 may be different from all the other Twort-like viruses characterized so far.
3.5. Genes Interrupted by Self-Splicing Elements
The presence of mobile splicing elements in the genomes of Twort-like viruses is a characteristic
feature of staphylococcal myoviruses [17–19]. In the case of fRuSau02 phage, four protein-encoding
genes were found to be interrupted by different insertion sequences (Figure S1): (1) The gene encoding
phage lysin (Lys) is fragmented into two by an intron-encoded HNH homing endonuclease gene
(I-KsaI). (2) The terminase large subunit gene is divided by the intron, encoding I-MsaI, a protein of
unknown function. (3) The gene encoding the putative DNA polymerase-associated exonuclease (PolA)
contains two introns encoding proteins I-KsaII and I-KsaIII. (4) The gene encoding phage RecA-like
recombinase (Rec) contains the intron-encoded endonuclease gene I-MsaII. All of the intervening
sequences are predicted to be group I introns encoding putative endonucleases. The functionality of
the spliced genes was shown by the fact that the presence of full proteins encoded by three out of
four spliced genes was observed in the LC-MS/MS analysis. Namely, lysin, terminase large subunit,
and phage recombinase were among the proteins identified in the LC-MS/MS analysis of the purified
phage particles (Table 1), with peptides present in both the C- and N-terminal parts of the proteins
(see below). While this does not conclusively prove that the polypeptides are continuous, this is the
most likely option. The gene splicing pattern of lysin and polymerase encoding genes is identical
to the one presented by staphylococcal phages G1, K and ISP [19,47,48]. However, fRuSau02 has
additional insertions in the terminase large subunit and recombinase genes that were also present in
phage Team1. Unlike in the more distant phages Remus/Romulus and Twort, there were no intein
domains identified in the fRuSau02 genome [17,49,50].
3.6. Proteomic Analysis of the Phage Structural Proteins
To confirm the identification and expression of the phage structural proteins, a proteomic analysis
of the purified phage particles using LC-MS/MS was performed. The comparative analysis of obtained
peptide sequences with the sequences of predicted phage proteins allowed for the identification of
these structural proteins. To exclude the possibility of obtaining false positive results due to similarity
with bacterial proteins that could be carried over from the lysate during the sample preparation,
the obtained peptide sequences were compared simultaneously against the phage and bacterial
protein sequences. Altogether, 81 phage proteins were identified in the LC-MS/MS analysis, of which
78 fulfilled the inclusion criteria (>2 unique peptides and/or >5% coverage) (Table 1). The analysis of
the structural proteome identified the capsid (Mcp) and the tail (Tsp, TmpA, TmpB, TmpC, TmpD,
TmpE, TmpF, TmpG, TmpH, BmpA, BmpB, BmpC) proteins, receptor binding proteins (RS_124 and
RS_126), the portal protein (Prt), and putative membrane proteins (MbpC, MbpD, MbpG, MbpH, MbpR,
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MbpS), as well as phage holin (HolA). Additionally, this study showed the presence of ribonucleotide
reductases (NrdE and NrdF), DNA-binding protein (HmzG), putative ligase (Lig), recombination
nuclease B (RncB), ribonuclease H (Rbn), and DNA helicases (DhlA and DhlB) as well as sigma and
anti-sigma factors (Sig, Asf). Altogether, 33 of the identified proteins were annotated as novel phage
structural proteins. As already described above, the LC-MS/MS analysis showed also the presence
of three proteins: the phage lysin (LysK), terminase (Ter) and recombinase (Rec) encoded by the
genes interrupted by the intervening sequences. The prohead protease Pro was also identified in
the LC-MS/MS analysis. The presence of the protease among the structural proteins was described
previously for Lactobacillus delbrueckii-specific phages [51,52] but may be the result of lack of dissociation
from the head after the assembly.
3.7. fRuSau02 Host Range
A collection of 135 Staphylococcus strains, including 51 human and 54 porcine S. aureus isolates
and 30 coagulase-negative Staphylococcus strains of human origin were used to assess the host range
(Table 2). Of the 50 clinical S. aureus strains collected for this study, 35 were methicillin-sensitive and
15 methicillin-resistant (Table S1). Phage fRuSau02 was able to infect 49 (96%) coagulase-positive and
15 (50%) coagulase-negative strains of human origin, whereas the rate of infection of pig isolates was
much lower with only 18 (33%) strains infected. The infectivity of S. aureus strains did not depend
on their response to methicillin. Some of the bacterial strains instead of clear lysis displayed turbid
lysis or only slower growth rate. Counting together the clear and turbid lysis, 33 (61%) of pig isolates
and 5 (17%) of coagulase-negative strains were resistant to phage infection. Importantly, all S. aureus
human isolates (including MRSA strains) were at least moderately sensitive to fRuSau02. Further,
patient isolates of coagulase-negative Staphylococcus strains, including S. intermedius, S. lugdunensis,
S. epidermidis, S. haemolyticus, S. saprophyticus and S. pseudointer, showed different rates of infection
depending on the strain, however, at least one strain of each species was susceptible to the phage.
Further, the coagulase-negative strains and several pig isolates displayed lower efficiency of infection
and turbidity of the plaques, while human S. aureus isolates were characterized by big (1–3 mm) clear
plaques (data not shown).
Table 2. The infectivity of fRuSau02 for different staphylococcal isolates. The details and strain
references are listed in supplementary material Table S1.
fRuSau02 Infectivity
Bacterial Hosts Infected * Intermediate * Resistant *
Coagulase-Positive Human Isolates (n = 51)
S. aureus 49 (96%) 2 (4%) 0 (0%)
Coagulase-Negative Human Isolates (n = 30)
S. intermedius 0 3 2
S. lugdunensis 1 4 0
S. epidermidis 0 1 4
S. haemolyticus 0 2 3
S. saprophyticus 1 2 2
S. pseudointer 0 4 1
ALL 2 (7%) 16 (53%) 12 (40%)
Coagulase-Positive Porcine Isolates (n = 54)
S. aureus 18 (33%) 3 (6%) 33 (61%)
* Infected indicates clear lysis or growth inhibition for spot and liquid assays, respectively, intermediate turbid lysis
or slower growth rate, and resistant no infection.
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3.8. fRuSau02 Receptor
Staphylococcal Twort-like phages have been shown to utilize cell wall teichoic acids (WTAs) as
their receptors [22]. To test whether this is also the case with fRuSau02, we analyzed the infectivity
of fRuSau02 in S. aureus strain tagO. This strain carries a mutation in the gene encoding TagO, an
enzyme that catalyzes the transfer of N-acetylglucosamine to bactoprenol in the first step of teichoic
acid biosynthesis [53,54]. As shown in Figure 6A, the phage failed to reproduce in the tagO strain.
Furthermore, the adsorption assay revealed that fRuSau02 was not able to adsorb to this strain
(Figure 6B). It thus seems that like for other staphylococcal Twort-like phages, WTAs serve as receptors
for fRuSau02.
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Figure 6. Suitability of host strains for production of fRuSau02. (A) The efficiency of plating (EOP)
counted as the number of plaque-forming units (PFU) obtained from the same amount of phage
lysate for different bacterial strains. The result obtained for the reference strain 13KP was set as 100%;
(B) Adsorption of fRuSau02 to bacterial surface. Ctrl represents LB as negative control, in which the
residual PFU was set to 100%; (C) The titer of fRuSau02 lysate produced in strains 13KP and TB4.
Error bars indicate SD, p-values the level of significance between 13KP and other strains, *** indicates
that the difference is statistically significant at the p-value < 0.001 level.
3.9. The Choice of Optimal Host Strain for Therapeutic Phage Production
In an ideal situation, host strains used for the production of therapeutic phages should be free of
prophages. This is bec use prophages encode virulence factors, such as staphylococcal enterotoxins [55].
In addition, th y can be induced from cells during the inf ction by therapeutic phage and cause genome
variati ns [56]. To study the possibility to produce fRuSau02 in the p ophag -fre S. aureus strain, we
compared the efficiency of plating (EOP) in strains 13KP, Newman, and TB4. Of these, 13KP is the
strain that was used as a host strain during the phage isolation, a d it was used as a control strain
with 100% EOP. TB4 is a prop age-free strain [53] and Newman the pare tal strain for TB4 [57].
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The EOP assay showed that both TB4 and Newman had reduced infectivity compared to the
reference strain 13KP (Figure 6A). This was not due to the lowered adsorption efficiency of fRuSau2
to these strains, as the adsorption assay did not reveal significant difference between 13KP and TB4.
The phage adsorption to Newman was significantly reduced from 13KP, even though the residual PFU
even in this strain was only 0.8% (Figure 6B). The potential of TB4 strain for phage production was
further studied by preparing phage stocks. Semi-confluent soft-agar overlay plates were prepared
using host-strain adjusted amount of fRuSau02 bacteriophage. Phage stocks were prepared in three
parallels and titrated (Figure 6C). The results showed that the difference in the amount of phage
obtained using 13KP and TB4 as host was statistically significant (p = 0.020), however even the titer
obtained in TB4 was sufficient for phage production purposes.
As genes for bacterial toxins often reside in prophage genomes, we wanted to analyze whether
fRuSau02 lysate produced in TB4 strain contains less toxins than the lysate produced in 13KP or
Newman strains. To this end, the staphylococcal enterotoxins were measured from the phage lysates
with the Transia Plate Staphylococcal Enterotoxins assay that detects enterotoxins A, B, C, D, and
E. The phage lysate produced in 13KP was clearly positive for enterotoxins, with a concentration
that approximately corresponded to 320 ng/mL of staphylococcal enterotoxin A. The phage lysate
produced in Newman strain had clearly less toxins (~6 ng/mL) and the lysate produced in TB4
remained negative, indicating that the enterotoxin concentration was lower than the detection limit
of the assay (~1 ng/mL of enterotoxin A). It should be noted here that the assay is not validated for
quantitative analysis, thus the concentrations need to be considered approximates.
To conclude, strain TB4 should be considered as potential bacterial host for the production of
bacteriophage preparations for phage therapy, as it does not possess the risk of temperate phage or
enterotoxin carry-over.
4. Discussion
This study reports a new bacteriophage, fRuSau02, isolated from a commercial Staphylococcus
bacteriophage cocktail produced by Microgen. The genomic analysis revealed that fRuSau02 is very
closely related to phage MSA6 and many other Twort-like viruses. Bacteriophage fRuSau02 possesses a
large genome (148,464 bp) with typical modular organization and a low G+C content and therefore can
be classified as a member of the genus Twortlikevirus. In coherence, the morphology of the fRuSau02
phage is similar to MSA6 [20], as well as the staphylococcal phage K [19] and Listeria phage A511 [58].
The phylogeny analysis of 35 Twort-like phages clustered fRuSau02 and MSA6 in a same species
together with A5W, Staph1N, Fi200W, and 676Z. Phage Twort, the type representative of this genus, is
more distantly related to fRuSau02, the two phages displaying only 46.5% identity at the nucleotide
level. Perhaps the most significant difference between fRuSau02 and MSA6 was the H306P change
in the putative receptor binding protein (RS_124 and ORF094 in fRuSau02 and MSA6, respectively).
Histidine in position 306 seems unique for fRuSau02, as homologous proteins of other Twort-like
viruses analyzed so far, for example G1ORF008 of phage G1, ORF107 of Sb-1, and ORF125 of Team1, all
have P306. The preliminary structural modelling indicated the H306P change alters the structure of the
carbohydrate-binding region of the RBP, which may have a profound effect on the phage host range.
The in silico analysis revealed the presence of bacterial promoters in the genome of fRuSau02.
However, both the presence of genes encoding for the phage sigma and anti-sigma factors and
the genomic region of 27.5 kb that does not contain any promoters suggest the existence of phage
promoters. Although the performed bioinformatics study failed to reveal any conserved sequences
present upstream of the genes of this module, we believe that fRuSau02 possesses two types of
promoters. Most likely, in the beginning of the infection process viral genes are transcribed by the
bacterial sigma factor. During this step, the sigma and anti-sigma factors encoded by the phage
genome are also transcribed. In the later stages of infection, the anti-sigma factor inhibits the activity
of the bacterial factor and allows the phage sigma factor to lead the transcription from its own
unique promoters. Such a process would allow the bacteriophage to have a high and uniform rate of
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transcription of late structural genes with a minimal transcription of bacterial genes. Further studies
aiming at the recognition of transcriptional starting sites are needed to indicate the possible viral
promoters and to validate the annotated bacterial promoters.
The LC-MS/MS analysis revealed 78 phage structural proteins. Due to the high sensitivity of
the method, we have to take into consideration the possibility that some of the identified proteins are
carried over from the lysate and co-isolated with the phage particles. On the other hand, previous
studies showed that some proteins are commonly packed together with the DNA due to their
association with nucleic acids [59,60]. For example, the phage sigma and anti-sigma factors (RS_157
and RS_133, respectively) were among the proteins identified, however, it is not likely that they are
structural proteins of the phage particles. Earlier studies showed that the primary staphylococcal
polymerase σSA, directs transcription of early genes in Twort-like viruses [47]. In addition, both
bacterial RNA polymeras (RNAP) subunits and the sigma factor were among the bacterial proteins
identified in the LC-MS/MS study (data not shown) suggesting that these proteins were co-isolated
together with the phage particles. It is possible that these proteins show physical properties that
make them either more prone to be co-isolated with phage particles during the purification process
or they display unspecific binding to the capsid proteins. Similarly, the proteome analysis showed
the presence of putative membrane proteins (MbpC, MbpD, MbpG, MbpH, MbpR, MbpS) that can
be a part of the structural proteome used during the infection step or during the assembly and lysis.
However, due to the fact that they bind to the membranes, it is also possible that they were carryover
from the phage lysate.
Phage fRuSau02 was shown to infect a considerable number of human S. aureus isolates, however,
the rates of infectivity were much lower among the animal isolates. Similar host range pattern has
earlier been observed with phage ISP, which also infects efficiently human S. aureus isolates but is
unable to infect S. aureus strains isolated from pigs [48]. The resistance of the pig strains may be due to
minor structural differences of WTA between different S. aureus strains. It is also plausible that some
strains developed phage resistance without the introduction of modifications in the phage receptor
structures. For example, the presence of CRISPR sequences in the genome of S. aureus allows the
bacteria to acquire the immunity against encountered phages [61]. The pig MRSA strains often belong
to only few clonal complexes [62], which may explain their different phage profile compared to S.
aureus stains isolated from other sources. Interestingly, the host profile of fRuSau02 may be somewhat
different from ISP, as fRuSau02 was also able to infect some coagulase-negative staphylococcal strains,
including S. haemolyticus earlier shown to be resistant for ISP [48].
Phages have important potential as antimicrobial agents and may serve as an alternative to
antibiotics, especially in case of multi-drug resistant pathogens. Phage therapy is a possible cure for
community-acquired and nosocomial infections caused by drug-resistant Staphylococcus, as well as a
good candidate for prevention of bacterial contamination in industry and animal husbandry [53–67].
Twort-like phages are perhaps the most studied S. aureus phage group for clinical applications [15]. For
example, phage ISP is one component of a phage therapy cocktail BFC-1, developed for the treatment
of burn wound infections [68,69].
To conclude, both our analyses and the fact that fRuSau02 was isolated from a commercial
therapeutic phage cocktail suggest that it should be considered as well suited for human phage
therapy against coagulase-positive and to some extent also coagulase-negative staphylococcal strains.
However, its capacity for the prevention and control of MRSA carriage and/or contamination in the
animal husbandry and food industry may be more limited. The efficacy and safety of fRuSau02 as
the therapeutic tool is still to be elucidated. Further research that includes pharmacological trials is
essential to confirm the possible role of fRuSau02 in the treatment of different forms of MRSA infections
in humans.
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